Japanese Enceph Vacc Sa14-14-2, Inactivated Dosage

Medically reviewed by Drugs.com. Last updated on Jan 13, 2022.

Usual Adult Dose for Japanese Encephalitis Virus Prophylaxis

Primary Series: Two 0.5 mL doses intramuscularly 28 days apart

Booster Dose: May give a booster dose if the primary 2 dose series was completed more than 1 year previously and ongoing exposure to Japanese encephalitis virus (JEV) is expected.

Comments: The primary immunization series should be completed at least 1 week prior to potential exposure.

Usual Pediatric Dose for Japanese Encephalitis Virus Prophylaxis

Primary Series:
3 years of age and older: Two 0.5 mL doses intramuscularly 28 days apart
2 months to less than 3 years of age: Two 0.25 mL doses intramuscularly 28 days apart

Booster Dose:
17 years of age and older: May give a booster dose if the primary 2 dose series was completed more than 1 year previously and ongoing exposure to Japanese encephalitis virus (JEV) is expected.
2 months to under 17 years: The safety and immunogenicity of a booster dose has not been evaluated.

Comments: The primary immunization series should be completed at least 1 week prior to potential exposure.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

CONTRAINDICATIONS:

Severe allergic reactions (e.g. anaphylaxis) to any of the ingredients or to any other Japanese encephalitis virus vaccine
Consider an allergist referral for patients allergic to another Japanese encephalitis vaccine to determine if this vaccine is appropriate; uncertainty is possible as to which vaccine component lead to the allergic reaction.

Safety and efficacy have not been established in patients younger than 2 months.

To report suspected adverse reactions, contact the Vaccine Adverse Event Reporting System (VAERS) at: https://vaers.hhs.gov

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

Administer intramuscularly
Do not administer intravenously, intradermally or subcutaneously
Preferred sites for IM injection: The anterolateral aspect of the thigh in infants 2 to 11 months of age, the anterolateral aspect of the thigh or the deltoid muscle (if muscle mass is adequate) in children 1 to less than 3 years of age, or the deltoid muscle in individuals 3 years of age and older

Storage requirements: